COMBINATION PREPARATIONS WITH CYTOKINE ANTAGONIST AND CORTICOSTEROID Russian patent published in 2014 - IPC A61K31/573 A61K38/20 A61P19/00 A61P19/02 A61P19/08 A61K38/30 

Abstract RU 2526161 C2

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to treating arthropathies, such as arthrosis and inflammatory loss of cartilage, tendon disorders and/or degenerative spine diseases. What is presented is a pharmaceutical composition for the above application, containing a corticosteroid and a cytokine antagonist - a natural or recombinant protein of interleukin IL-1Ra antagonist, particularly orthokine or anakinra, and optionally a growth factor; the composition is injectable into an injured nerve root, or into an injured intervertebral disk, or into their local context, or for intraarticular injection. There are presented: a kit comprising the pharmaceutical composition with the above cytokine antagonist and optionally the growth factor, and the pharmaceutical composition with the corticosteroid; using the above cytokine antagonist and optionally the growth factor for preparing the pharmaceutical composition to be used in combination therapy together with the corticosteroid for the above application; using the corticosteroid for preparing the pharmaceutical composition to be used in combination therapy with the above cytokine antagonist and optionally the growth factor for treating the above arthropathies, tendon disorders and/or degenerative spine diseases.

EFFECT: clinical success of treatment manifested by apparent joint detumescence, pain reduction by 60-100%, functional improvement of the joint, with the effect persisting 8 months later and more after the treatment.

39 cl, 1 tbl

Similar patents RU2526161C2

Title Year Author Number
COMBINATION DRUG CONTAINING CORTICOSTEROID AND EXOSOMES 2010
  • Veling Peter
  • Rajnekke Julio
RU2557897C2
AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE 2011
  • Barns, Tomas, M.
  • Khou, Tszinchzhao
  • King, Braken, M.
RU2754957C2
METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST 2013
  • Ardeleanu, Marius
  • Gandhi, Namita
  • Graham, Neil
  • Kirkesseli, Stephane, C.
  • Kundu, Sudeep
  • Radin, Allen
  • Rocklin, Ross, E.
  • Weinstein, Steven
  • Davidson Hamilton, Jennifer
  • Ming, Jeffrey
RU2801531C2
THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS 2018
  • Yoshimoto, Tomohiro
  • Palumbo, M. Joseph
  • Stone, I. Violetta
  • Kato, Toru
  • Yasuda, Koubun
RU2791705C2
NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES 2021
  • Kim, Yunki
  • Kim, Minsun
  • Kim, Ryuryun
  • Choi, Jaeyoung
  • Yim, Yeseal
  • Shim, Myungbo
  • Han, Daye
  • Im, Daeseong
  • Park, Sungjin
RU2822001C1
IMMUNOCYTOKINES AND THEIR USE 2021
  • Wu Ellen
  • Wu Xiaoyun
  • Wakefield John
RU2818371C1
INTERLEUKIN-18 OPTIONS AND METHODS FOR THEIR USE 2018
  • Ring, Aaron
  • Zhou, Ting
  • Fischer, Suzanne
RU2797536C2
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF 2020
  • U, Tintin
  • Li, Khao
  • Lyu, Syun
  • Tao, Vejkan
RU2824390C2
ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION 2016
  • Blend-Vord Filip
  • Kosmak Mikha
  • Kholms Stiv
  • Kirbi Ian
  • Kempbell Dzhejmi
  • Kin Lesli Syuzan
  • Tkachev Viktor
RU2725221C2
ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE 2019
  • Beaumont, Kevin Charles
  • Breen, Danna M.
  • Chabot, Jeffrey Raymond
  • He, Tao
  • Shchors, Ksenya
  • Apgar, James R.
  • Lambert, Matthew Allister
RU2795457C2

RU 2 526 161 C2

Authors

Veling Peter

Rajneke Julio

Dates

2014-08-20Published

2010-12-10Filed